IE800336L - Antihypertensive compositions - Google Patents
Antihypertensive compositionsInfo
- Publication number
- IE800336L IE800336L IE800336A IE33680A IE800336L IE 800336 L IE800336 L IE 800336L IE 800336 A IE800336 A IE 800336A IE 33680 A IE33680 A IE 33680A IE 800336 L IE800336 L IE 800336L
- Authority
- IE
- Ireland
- Prior art keywords
- salidiuretic
- antihypertensive compositions
- gb2044101a
- hydrobenzthiazide
- dopamide
- Prior art date
Links
- 230000003276 anti-hypertensive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 2
- ALAXZYHFVBSJKZ-UHFFFAOYSA-N endralazine Chemical compound C1CC=2N=NC(NN)=CC=2CN1C(=O)C1=CC=CC=C1 ALAXZYHFVBSJKZ-UHFFFAOYSA-N 0.000 abstract 2
- 230000000054 salidiuretic effect Effects 0.000 abstract 2
- SSEAPVMQZPKNQZ-UHFFFAOYSA-N 2-(aminomethyl)-4-tert-butyl-6-iodophenol Chemical compound CC(C)(C)C1=CC(I)=C(O)C(CN)=C1 SSEAPVMQZPKNQZ-UHFFFAOYSA-N 0.000 abstract 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 abstract 1
- ZUNJWRJEKCRIMZ-UHFFFAOYSA-N 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CSCC1=CC=CC=C1 ZUNJWRJEKCRIMZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 abstract 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 abstract 1
- 229960003515 bendroflumethiazide Drugs 0.000 abstract 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 abstract 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 abstract 1
- 229960001541 benzthiazide Drugs 0.000 abstract 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 abstract 1
- 229960004064 bumetanide Drugs 0.000 abstract 1
- 229960002155 chlorothiazide Drugs 0.000 abstract 1
- 229960001523 chlortalidone Drugs 0.000 abstract 1
- 229960003176 cyclothiazide Drugs 0.000 abstract 1
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 abstract 1
- -1 dopamide Chemical compound 0.000 abstract 1
- 229960002029 endralazine Drugs 0.000 abstract 1
- 229960003199 etacrynic acid Drugs 0.000 abstract 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 abstract 1
- 229960003883 furosemide Drugs 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002003 hydrochlorothiazide Drugs 0.000 abstract 1
- 229960003313 hydroflumethiazide Drugs 0.000 abstract 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003739 methyclothiazide Drugs 0.000 abstract 1
- 229960002817 metolazone Drugs 0.000 abstract 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002508 pindolol Drugs 0.000 abstract 1
- 229960005483 polythiazide Drugs 0.000 abstract 1
- 229920000046 polythiazide Polymers 0.000 abstract 1
- 229960000577 quinethazone Drugs 0.000 abstract 1
- AGMMTXLNIQSRCG-UHFFFAOYSA-N quinethazone Chemical compound NS(=O)(=O)C1=C(Cl)C=C2NC(CC)NC(=O)C2=C1 AGMMTXLNIQSRCG-UHFFFAOYSA-N 0.000 abstract 1
- 229960000356 tienilic acid Drugs 0.000 abstract 1
- AGHANLSBXUWXTB-UHFFFAOYSA-N tienilic acid Chemical compound ClC1=C(Cl)C(OCC(=O)O)=CC=C1C(=O)C1=CC=CS1 AGHANLSBXUWXTB-UHFFFAOYSA-N 0.000 abstract 1
- 229960004813 trichlormethiazide Drugs 0.000 abstract 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Pharmaceutical compositions containing a) 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido-[4,3-c]pyridazine (endralazine) b) a salidiuretic and c) pindolol are useful for the treatment of hypertension. The salidiuretic may be 2-aminomethyl-4-tertbutyl-6-iodophenol, bendroflumethiazide, benzthiazide, bumetanide, chlorothiazide, chlorthalidone, dopamide, cyclothiazide, ethacrynic acid, furosemide, hydrobenzthiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, metolazone, polythiazide, quinethazone, ticrynafen or trichloromethiazide.
[GB2044101A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH178579A CH643457A5 (en) | 1979-02-22 | 1979-02-22 | PHARMACEUTICAL PREPARATIONS FOR TREATING HYPERTENSION. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE800336L true IE800336L (en) | 1980-08-22 |
| IE49073B1 IE49073B1 (en) | 1985-07-24 |
Family
ID=4218544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE336/80A IE49073B1 (en) | 1979-02-22 | 1980-02-20 | Antihypertensive pharmaceutical compositions |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS55115823A (en) |
| AT (1) | AT378915B (en) |
| AU (1) | AU538599B2 (en) |
| BE (1) | BE881763A (en) |
| CA (1) | CA1147657A (en) |
| CH (1) | CH643457A5 (en) |
| DE (1) | DE3005029C2 (en) |
| FR (1) | FR2449450A1 (en) |
| GB (1) | GB2044101B (en) |
| HU (1) | HU187271B (en) |
| IE (1) | IE49073B1 (en) |
| IL (1) | IL59432A (en) |
| IT (1) | IT1145433B (en) |
| MY (1) | MY8500619A (en) |
| NL (1) | NL8001000A (en) |
| NZ (1) | NZ192924A (en) |
| PH (1) | PH17118A (en) |
| PT (1) | PT70855A (en) |
| SE (2) | SE8001121L (en) |
| ZA (1) | ZA801018B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2537434A1 (en) * | 1982-12-09 | 1984-06-15 | Sandoz Sa | Endralazine pharmaceutical composition in depot form |
| TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| GB2367242B (en) * | 2000-09-21 | 2004-07-28 | Henderson Morley Res & Dev Ltd | Antiviral treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2458155A1 (en) * | 1973-12-19 | 1975-07-03 | Sandoz Ag | NEW PHARMACEUTICAL PREPARATIONS |
-
1979
- 1979-02-22 CH CH178579A patent/CH643457A5/en not_active IP Right Cessation
-
1980
- 1980-02-11 DE DE3005029A patent/DE3005029C2/en not_active Expired
- 1980-02-13 SE SE8001121A patent/SE8001121L/en not_active Application Discontinuation
- 1980-02-15 GB GB8005245A patent/GB2044101B/en not_active Expired
- 1980-02-18 BE BE1/9727A patent/BE881763A/en not_active IP Right Cessation
- 1980-02-19 NL NL8001000A patent/NL8001000A/en not_active Application Discontinuation
- 1980-02-20 PT PT70855A patent/PT70855A/en unknown
- 1980-02-20 IT IT47950/80A patent/IT1145433B/en active
- 1980-02-20 IE IE336/80A patent/IE49073B1/en unknown
- 1980-02-20 CA CA000346083A patent/CA1147657A/en not_active Expired
- 1980-02-20 NZ NZ192924A patent/NZ192924A/en unknown
- 1980-02-20 IL IL59432A patent/IL59432A/en unknown
- 1980-02-20 FR FR8003669A patent/FR2449450A1/en active Granted
- 1980-02-20 AU AU55742/80A patent/AU538599B2/en not_active Ceased
- 1980-02-21 HU HU80402A patent/HU187271B/en unknown
- 1980-02-21 JP JP1980480A patent/JPS55115823A/en active Pending
- 1980-02-21 PH PH23672A patent/PH17118A/en unknown
- 1980-02-21 AT AT0095580A patent/AT378915B/en not_active IP Right Cessation
- 1980-02-22 ZA ZA00801018A patent/ZA801018B/en unknown
-
1982
- 1982-04-15 SE SE8202357A patent/SE8202357L/en not_active Application Discontinuation
-
1985
- 1985-12-30 MY MY619/85A patent/MY8500619A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3005029A1 (en) | 1980-09-04 |
| AU538599B2 (en) | 1984-08-23 |
| AT378915B (en) | 1985-10-25 |
| HU187271B (en) | 1985-12-28 |
| IT8047950A0 (en) | 1980-02-20 |
| BE881763A (en) | 1980-08-18 |
| IL59432A (en) | 1984-08-31 |
| NZ192924A (en) | 1984-05-31 |
| ZA801018B (en) | 1981-09-30 |
| JPS55115823A (en) | 1980-09-06 |
| IT1145433B (en) | 1986-11-05 |
| PH17118A (en) | 1984-06-01 |
| AU5574280A (en) | 1980-08-28 |
| DE3005029C2 (en) | 1987-02-12 |
| FR2449450B1 (en) | 1983-07-22 |
| GB2044101A (en) | 1980-10-15 |
| FR2449450A1 (en) | 1980-09-19 |
| IE49073B1 (en) | 1985-07-24 |
| PT70855A (en) | 1980-03-01 |
| CH643457A5 (en) | 1984-06-15 |
| MY8500619A (en) | 1985-12-31 |
| SE8202357L (en) | 1982-04-15 |
| ATA95580A (en) | 1985-03-15 |
| IL59432A0 (en) | 1980-05-30 |
| SE8001121L (en) | 1980-08-23 |
| CA1147657A (en) | 1983-06-07 |
| NL8001000A (en) | 1980-08-26 |
| GB2044101B (en) | 1983-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998045276A3 (en) | 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors | |
| Margolius et al. | Urinary kallikrein excretion in hypertensive man: relationships to sodium intake and sodium-retaining steroids | |
| LU90266I2 (en) | Composition comprising losartan potassium and hydrochlorothiazide or their pharmaceutically acceptable derivatives (hyzaarÐ) | |
| CA2268954A1 (en) | Oxadiazoles, processes for their preparation and their use as medicaments | |
| KR970064606A (en) | Pharmaceutical compositions to improve morbidity and / or mortality | |
| UA41938C2 (en) | Pharmaceutical composition for treating viral infections, aids and/or aids-associated complex | |
| IE811275L (en) | Vinblastines | |
| NO155226C (en) | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS CONTAINING BENZODIAZEPINES, DIBENZOTIEPINES OR QUINOLINMETANOL DERIVATIVES. | |
| CA2216535A1 (en) | Protein kinase c inhibitors | |
| AU551241B2 (en) | Preparation of liposomal medicaments | |
| Hilliard et al. | A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase | |
| TR199600970A2 (en) | The new crystal modification of CDCH, a process for its preparation and pharmaceutical formulations containing this modification. | |
| Schein et al. | Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report | |
| NO882075L (en) | 9-ALFA-HYDROXYSTEROIDS, THEIR PREPARATION, A PROCEDURE FOR THE PREPARATION OF THE SIMILAR 9 (11) DEHYDRODY DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THE COMPOUNDS. | |
| HUP9802221A2 (en) | Markfortin and paraherkwamide derivatives with anti-parasitic effect | |
| JPH09323930A5 (en) | ||
| NO952743L (en) | New benzothiadiazine compound, its preparation and pharmaceutical preparations | |
| CA2094806A1 (en) | Aminosulfonyl urea acat inhibitors | |
| EP0124314A3 (en) | Substituted-3H-indeno(1,2-c)pyridazin-3-ones | |
| IS5390A (en) | Benzoxazine and benzothiazine derivatives and their use in medicine | |
| NO871664D0 (en) | PROCEDURE FOR THE PREPARATION OF DOPA-CONTAINING BIOADHESIVE PROTEINS FROM TYROSHEET PROTEINS. | |
| SU1675770A1 (en) | Method for preparation of agent for visual detection of cholesterol on the skin surface | |
| Johannssen et al. | Localisation of the active site of pyruvate carboxylase by electron microscopic examination of avidin‐enzyme complexes | |
| HK98995A (en) | Low dose benazepril/thiazide diuretic composition | |
| Vega et al. | Antihypertensive agents: Pyridazino (4, 5-b) indole derivatives |